当前位置: 首页 > 详情页

In vitro-induced M2 type macrophages induces the resistance of prostate cancer cells to cytotoxic action of NK cells

文献详情

资源类型:

收录情况: ◇ SCIE

机构: [a]Department of Radiation Oncology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA [b]Department of Urology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, PR China
出处:
ISSN:

关键词: IL-6 Macrophages CRPC NK cell cytotoxicity PD-L1 NKG2D

摘要:
Previous reports, including our experimental results, showed that macrophages migrate to prostate cancer (PCa) cells. We tested whether the migrated macrophages affect the susceptibility of castration-resistant PCa (CRPC) cells to cytotoxic actions of natural killer (NK) cells. We found treatment of tumor cells with the conditioned media (CM) of the PMA/IL-4 treated THP-1 cells (M2 type macrophages) (THP-1 CM) decreased the susceptibility of tumor cells to NK cell cytotoxicity, as a result of increased programmed death receptor ligand 1 (PD-L1) and decreased NK group 213 (NKG2D) ligands in CRPC cells. Meanwhile, the decreased susceptibility of tumor cells was also detected when NK cells were treated with THP-1 CM and used in NK cell cytotoxicity tests. Therefore, we observed higher resistance of CRPC cells when both tumor and NK cells were treated with THP-1 CM than when tumor cells or NK cells were individually treated. We further discovered that the PMA/IL-4 treated THP-1 cells secrete a high level of IL-6, so blocking the IL-6 action significantly decreased the PD-Ll level while recovering the NKG2D ligands, thus increasing the susceptibility of CRPC cells to NK cell action. Moreover, we discovered that JAK-Stat3 is the most critical IL-6 downstream signaling in triggering the THP-1 CM effect. Consequently, we found the susceptibility of CRPC cells to NK cells was increased when either JAK or Stat 3 inhibitor was added when tumor cells were treated with THP-1 CM, and that the best effect was observed when the JAK inhibitor and PD-Ll Ab were added together.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2017]版:
大类 | 2 区 医学
小类 | 3 区 肿瘤学 4 区 细胞生物学
最新[2023]版:
大类 | 3 区 生物学
小类 | 4 区 细胞生物学 4 区 肿瘤学
JCR分区:
出版当年[2016]版:
Q2 ONCOLOGY Q2 CELL BIOLOGY
最新[2023]版:
Q2 ONCOLOGY Q3 CELL BIOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2016版] 出版当年五年平均 出版前一年[2015版] 出版后一年[2017版]

第一作者:
第一作者机构: [a]Department of Radiation Oncology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA [b]Department of Urology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, PR China
通讯作者:
通讯机构: [a]Department of Radiation Oncology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16409 今日访问量:0 总访问量:869 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院